About Alexion

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Alexion developed the world’s first and only terminal complement inhibitor from laboratory through regulatory approval and commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (refractory gMG). Alexion also has two highly innovative enzyme replacement therapies for the treatment of patients with hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

We are committed to investing in ongoing research and development focused on innovative therapies with life-changing potential. Our internal research efforts are focused on leveraging our 20+ years of experience in complement biology, and our development efforts focus on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. We are working to expand our approved complement inhibitor into new complement indications while strengthening our clinical-stage pipeline through internal and external development opportunities in our four core areas.

Alexion has approximately 3,000 employees worldwide and operations in place to serving patients in 50 countries. Visit our corporate website for more information about Alexion globally.

Alexion in Europe

Learn about Alexion in Europe, which includes several key global and regional functions as well as local in-country operations to serve patients internationally and across Europe.

Learn More

Transparency and Disclosure

Alexion is committed to operating with integrity, accountability and transparency, and to complying with all applicable laws and regulations throughout Europe. View our disclosures of financial support to healthcare professionals and patient organizations.

Review required disclosures for the following regional locations: